Erdogan, SuatSerttas, RizaTurkekul, KaderDibirdik, Ilker2024-06-122024-06-1220220301-48511573-4978https://doi.org/10.1007/s11033-022-07343-yhttps://hdl.handle.net/20.500.14551/18680Background Tumor-initiating or cancer stem cells (CSCs) reduce the effectiveness of conventional therapy. Thus, it is crucial to eliminate CSCs while killing bulky cancer cells using a combination of conventional chemotherapy and anti-CSC drugs. Salinomycin is a selective inhibitor against CSCs and shows promise in combination applications. The aim of the study was to examine the efficacy of co-administered cabazitaxel and salinomycin on the survival of prostate cancer cells and CSCs. Methods and Results CD44 + stem cells were isolated from human PC3 prostate cancer cells by using magnetic activated cell sorting. The cells were concomitantly exposed to salinomycin and cabazitaxel, and the cell survival was determined by MTT test. Apoptosis was assessed by image-based cytometer, and cell migration was evaluated by wound healing assay. The expression of target mRNA and protein were assessed by RT-qPCR and Western blot, respectively. Combination index (CI) analysis showed that simultaneous administration of salinomycin and cabazitaxel was able to exert strong synergistic effect on CD44 + subpopulation (CI = 0.33), but no synergism was observed in PC3 cells. The combination of the two agents significantly increased Bax, cytochrome c, caspase-3 and - 8 mRNA expression in CD44 + CSCs, causing apoptosis. The applied therapy strategy strongly inhibited the phosphorylation of Akt, protein expression of Akt1, NF-kappa B and Wnt. Conclusions In conclusion, our data suggest that combining salinomycin with cabazitaxel shows promise as a prostate cancer treatment approach that can target CSCs.en10.1007/s11033-022-07343-yinfo:eu-repo/semantics/closedAccessApoptosisCabazitaxelCancer Stem CellCD44Prostate CancerSalinomycinStem-CellsDocetaxelApoptosisMigrationNanoparticlesSurvivalDeliveryTargetArticle49648734884Q3WOS:0008114159000042-s2.0-8513219788235705771Q2